Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 172 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
MOLECURE Aktie jetzt für 0€ handeln | |||||
15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 282 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen | |
31.07.24 | Avicenna Biosciences, Inc.: Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs | 478 | Business Wire | Molecure S.A. ('Molecure', SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research collaboration to facilitate the discovery and development... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CO.DON | 0,022 | +18,92 % | CO.DON GmbH ist Partner des EU-geförderten Projekts zur Weiterentwicklung des 3D-Bioprinting für die Geweberegeneration | Teltow (ots) - Das im Dezember 2024 gestartete EU-geförderte Projekt micro2MACRO (m2M) zielt darauf ab, die Geweberegeneration durch eine innovative Bioprinting-Plattform voranzutreiben. m2M konzentriert... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,455 | +0,69 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
IMMATICS | 4,778 | +0,67 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
ALDEYRA | 3,446 | +1,80 % | Aldeyra-Aktie steigt nach FDA-Vereinbarung zum Krebsmedikament-Studiendesign | ||
MEDIFAST | 12,230 | -1,29 % | MEDIFAST INC - 8-K, Current Report | ||
PHARMING | 0,892 | -0,50 % | Pharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders | Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM)... ► Artikel lesen | |
COHERUS ONCOLOGY | 0,657 | -2,17 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
ORUKA THERAPEUTICS | 10,600 | +7,61 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer | MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard... ► Artikel lesen | |
DBV TECHNOLOGIES | 1,660 | -0,12 % | DBV Technologies stock holds steady as JMP reiterates $21 price target | ||
INNOVIVA | 16,300 | -0,61 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
ARMATA PHARMACEUTICALS | 1,540 | +2,67 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met
AP-SA02 arm significantly improved clinical outcomes... ► Artikel lesen | |
BRAINSTORM CELL THERAPEUTICS | 1,050 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn | NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative... ► Artikel lesen | |
SIGA TECHNOLOGIES | 6,680 | +2,93 % | Dividendenbekanntmachungen (15.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 1&1 AG DE0005545503 - 0,05 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0536 EUR ADMIRAL GROUP PLC GB00B02J6398 0,914 GBP 1,0846... ► Artikel lesen | |
LIQUIDIA | 10,170 | +0,20 % | Liquidia ernennt Dana Boyle zur Leiterin der Buchhaltung | ||
SYNDAX PHARMACEUTICALS | 7,750 | +1,31 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |